1,463 results on '"Moliterno, David"'
Search Results
202. Randomized Trial versus Registry Data—Comparing Apples and ORCHIDs
203. Imminent Extinction of Brachy(saurus)therapy for the Treatment of In-Stent Restenosis
204. International variation in invasive care of the elderly with acute coronary syndromes
205. The Relationship of Obesity to Ischemic Outcomes Following Coronary Stent Placement in Contemporary Practice
206. Brachytherapy for In-Stent Restenosis: A Distant Second Choice to Drug-Eluting Stent Placement
207. Are tirofiban and abciximab identical in efficacy?
208. Drug-Eluting Coronary Stents
209. Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up
210. Renal function, concomitant medication use and outcomes following acute coronary syndromes
211. Clopidogrel for Percutaneous Coronary Revascularization: Time for More Pretreatment, Retreatment, or Both?
212. Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel
213. Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials
214. Diabetes and coronary revascularization: defining optimal revascularization modality and adjunctive medical treatment
215. Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration
216. Outcomes in African Americans and whites after percutaneous coronary intervention
217. Fractionating Heparin
218. Fractionating Heparins and Their Clinical Trial Data—Something for Everyone
219. Diabetes and percutaneous coronary intervention: The sweet smell of success?
220. Coronary-artery vasoconstriction induced by cocaine, cigarette smoking or both
221. Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes
222. Troponins in Acute Coronary Syndromes: More TACTICS for an Early Invasive Strategy
223. Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels
224. Lamifiban: A Viewpoint by David J. Moliterno
225. Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry
226. Dual Antiplatelet Therapy
227. Mitral Regurgitation and Evolving Transcatheter Treatments
228. DUAL ANTIPLATELET THERAPY (DAPT) CESSATION AND CARDIOVASCULAR RISK IN RELATION TO AGE: ANALYSIS FROM THE PARIS (PATTERNS OF NON-ADHERENCE TO ANTI-PLATELET REGIMENS IN STENTED PATIENTS) REGISTRY
229. Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial
230. Being a Great Reviewer
231. Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention
232. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study
233. Prognostic significance of elevated troponin i after percutaneous coronary intervention
234. TCT-39 Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index: TWILIGHT-BMI Analysis
235. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update.
236. Preinfarction Angina
237. Prasugrel versus clopidogrel in primary PCI: Considerations of the TRITON-TIMI 38 substudy
238. Influence of intranasal cocaine on plasma constituents associated with endogenous thrombosis and thrombolysis
239. Coronary Vasospasm—Relation to the Hyperthyroid State
240. Achieving tissue-level perfusion in the setting of acute myocardial infarction
241. Year 1
242. Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial
243. TCT-110 Incidence, predictors, and outcomes of DAPT disruption due to non-compliance versus bleeding after PCI: insights from the PARIS Registry
244. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
245. Discharge timing and outcomes after uncomplicated non–ST-segment elevation acute myocardial infarction
246. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention
247. Images in Intervention
248. INCIDENCE, PATTERNS AND ASSOCIATIONS BETWEEN DUAL ANTIPLATELET THERAPY CESSATION AND RISK FOR ADVERSE EVENTS IN HIGH-RISK PATIENTS: INSIGHTS FROM THE PARIS REGISTRY
249. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention
250. State-of-the-Art Papers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.